Tunitas Therapeutics is a San Francisco, CA-based biopharmaceutical company focused on novel targeted protein therapeutics for allergy sufferers. The company is led by Nolan Sigal, M.D., Ph.D., President and Chief Executive Officer. Its lead candidate is a fusion protein called epsi-gam. Tunitas intends to use recent financing to advance epsi-gam through initial Phase 1 clinical trials and to initiate Phase 2a studies. The company plans to develop epsi-gam as a potential treatment for patients with moderate to severe asthma and for patients with severe, potentially life-threatening food allergies. Tunitas closed a $10M Series A venture financing to support these development milestones.

Total raised

$10M

Funding rounds

1

Latest round

Series A

Latest activity

Sep 2015